0000899243-20-011324.txt : 20200427 0000899243-20-011324.hdr.sgml : 20200427 20200427060549 ACCESSION NUMBER: 0000899243-20-011324 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200415 FILED AS OF DATE: 20200427 DATE AS OF CHANGE: 20200427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BUCHI J KEVIN CENTRAL INDEX KEY: 0001209726 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39267 FILM NUMBER: 20817083 MAIL ADDRESS: STREET 1: 41 MOORES ROAD CITY: FRAZER STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Benitec Biopharma Inc. CENTRAL INDEX KEY: 0001808898 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LEVEL 14, 114 WILLIAM ST CITY: MELBOURNE, VIC STATE: C3 ZIP: 3000 BUSINESS PHONE: 61(0)3 8692-7222 MAIL ADDRESS: STREET 1: LEVEL 14, 114 WILLIAM ST CITY: MELBOURNE, VIC STATE: C3 ZIP: 3000 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-04-15 0 0001808898 Benitec Biopharma Inc. BNTC 0001209726 BUCHI J KEVIN C/O BENITEC BIOPHARMA INC. 3940 TRUST WAY HAYWARD CA 94545 1 0 0 0 Common Stock 4827 D Options (Right to Buy) 365.04 2020-11-12 Common Stock 2800 D These options were originally granted for exercise of ordinary shares of Benitec Biopharma Limited (predecessor to Issuer). Pursuant to a scheme of arrangement (the "Scheme") completed on April 15, 2020, all ordinary shares of Benitec Biopharma Limited were exchanged for shares of common stock in Issuer and no ordinary shares of Benitec Biopharma Limited remain outstanding. These options were granted to the Reporting Person on November 12, 2015, by Benitec Biopharma Limited. All options are fully vested. These options were originally granted for exercise of 840,000 underlying shares of Benitec Biopharma Limited's ordinary shares. Pursuant to the Scheme referenced in footnote 1, on April 15, 2020, all ordinary shares in Benitec Biopharma Limited were exchanged for shares of common stock in Issuer at an exchange rate of 300 ordinary shares for one share of common stock (the "Exchange Ratio"). As a result, the shares of common stock in Issuer now underlying these options is 2,800. Representing the exercise price to purchase one share of common stock of Issuer, calculated based on the certified exchange rate for April 15, 2020, as published by the Federal Reserve Board of the United States, of AUD 0.6328 to USD 1.00. These options were originally granted with an exercise price of AUD 0.77 per option to purchase an ordinary share in Benitec Biopharma Limited. Following the completion of the Scheme, the exercise price for one share of common stock of Issuer shall therefore be AUD 231.00, or USD 365.04 based on the aforementioned exchange rate, which equals to AUD 0.77 multiplied by the Exchange Ratio noted in footnote 3. /s/ J. Kevin Buchi 2020-04-27